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Vaccines are a group of
pharmaceuticals that include some of
the oldest biologically-made
compounds. The Smallpox vaccine was
introduced by Edward Jenner as early
as in 1796 and Louis Pasteur created
the first live attenuated bacterial
(Chicken Cholera) and viral (Rabies)
vaccines at the end of the 19th century.
A vaccine contains an antigen that is
capable of inducing an immune response in a living organism and as such, typically
enhances the organism’s ability to fight off or minimize disease. These antigens can be
live attenuated (weakened) microorganisms such as in the MMR (Measles, Mumps,
Rubella) virus vaccine, inactivated microbes (bacteria, virus) or parts thereof (proteins,
polysaccharides) such as the DTaP (Diphtheria, Tetanus, acellular Pertussis) vaccine.
Vaccines are biologically active products designed to stimulate the immune system
against future invasion of a pathogen by inducing memory to specific antigens. Vaccines
may be produced from viral pathogens such as those causing polio, influenza and Lyme
Disease, or from bacterial pathogens such as pertussis, tetanus, diphtheria and anthrax.
Recombinant fermentation techniques such as those used for hepatitis vaccine, produce
highly purified antigen-specific subunits that stimulate immunity without concern of
pathogen infection. Vaccine production typically uses several filtration and purification
steps. To obtain a purified vaccine the selected microorganism must first be grown then
the selected antigen must be separated, purified, formulated and sterilized prior to
delivery.
The way a vaccine is manufactured, depends on the type of antigen that makes up the
vaccine. As there are many different types of antigens, there are correspondingly many
different vaccine manufacturing processes. Especially in human vaccines, manufacturing
processes have been customized and often are carried out in dedicated facilities.
Standardization of the processes and technologies in a way that makes maximum use of
existing facilities and equipment, and of a regulatory track record, could, however, bring
many benefits in term of cost reduction and speed-to-market. Animal vaccine
manufacturing has typically worked according to this platform approach, with
manufacturing in multi-product facilities.
Vaccines can be classified into general antigen groups and manufacturing methods, in
which some element of process standardization may exist: 
Viral vaccines and viral vectors (ex. Polio, MMR, Adenoviral vectors)
Microbial vaccines and toxoids (ex. DTaP)
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Recombinant Protein vaccines (ex. Hepatitis B and HPV)
Polysaccharide vaccines and conjugates (ex. Hib and Pneumococcal vaccines)
DNA vaccines & gene therapy (some animal vaccines, vaccines in development)
Vaccine manufacturing platform standardization is increasingly applicable to new
vaccines and vaccine concepts in the large developments pipeline. Possible standardized
unit operation steps include:
Upstream, producing the vaccine antigen in a well-characterized host cell line or
recombinant system, adapted for high cell densities in bioreactors, leading to high
yields
Downstream, by using modular, flexible and robust purification technologies
Antigen presentation & formulation, involving conjugation, folding in virus-like-
particles or virosomes, or making use of adjuvants and adjuvant systems like
emulsions and liposomes
Furthermore, buffer & media preparations, inactivation, and other process steps can be
standardized. To maximally take advantage of these capabilities, single-use
manufacturing technologies are recommended, allowing for increased flexibility in the
process, low cross-contamination risk with multi-products, maximum containment and
aseptic control, allowing manufacturing in lower cost class C environments.
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